Ben Bronstein, Director at Aldeyra Therapeutics, Inc. (ALDX), bought 4,444 shares at $4.50 ($20K) on 2017-02-17, disclosed to the SEC on 2017-02-21.
Open-market purchase of $20k ALDX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |